Related Experiment Video
Updated: Sep 3, 2025

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Cancer treatment-related cardiac dysfunction
Bernadette Brady1,2, Ross Murphy3
1Academic Department of Palliative Medicine, Our Lady's Hospice & Care Services, Dublin, Ireland bbrady@olh.ie.
Objectives:
This paper describes cardiotoxicity and cancer treatment-related cardiac dysfunction (CTRCD). Long-term sequelae of treatment are important, and changing, and may manifest when a patient is under the care of a supportive care service.
Methods:
Key messages for supportive and palliative care clinicians are outlined to facilitate identification and management of CTRCD.
Results:
Not all cardiotoxicity is alike. Types of cardiotoxicity, cardiac complications of immunotherapy, the challenge of autonomic nervous system dysfunction in cancer and management of cardiotoxicity are highlighted.
Conclusions:
The key strategies are early detection of cardiotoxicity, monitoring for development of CTRCD during treatment and surveillance in survivorship.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Cardiomyopathy V: Interprofessional Care

